A year in Oncology

A Review of 2020 Drug Approvals & Key Milestones
Ipsos infographic

Despite a global pandemic, 2020 saw a notable number of approvals of new anti-cancer therapies in the US, Europe and Japan – including the continued roll-out of immuno-oncology (I-O) therapies.

The US saw a similar number of new oncology drug/indication approvals in 2020 as in 2019. An even higher number were seen in Japan, largely due to approvals ahead of all other global regions (as per the Sakigake Designation Scheme) and the rollout of drugs already sanctioned by the FDA. In Europe, however, there were around a quarter fewer approvals in 2020 than in the prior year.

To view the approvals and the key milestones (in our view) in an easy-to-digest snapshot, please see Ipsos’ infographic, ‘A Year in Oncology: A Review of 2020 Drug Approvals in US, Europe & Japan’.

 

Download

The author(s)

More insights about Health

Related news

  • The Human Advantage Conference 2026: Highlights
    Artificial Intelligence (AI) Events replay

    The Human Advantage Conference 2026: Highlights

    Ipsos is proud to support The Human Advantage 2026, a flagship event bringing together some of the world's leading experts and key industry figures to explore how behavioural science, AI, and human intelligence can address the critical challenges facing businesses and society. Here's a look back at two days of live coverage.
  • [WEBINAR] KEYS: Dialling Up the S In Sustainability
    KEYS Events replay

    [REPLAY] KEYS: Dialling Up the S In Sustainability

    In the next episode of our KEYS webinar, we’ll be asking whether now is the time when organisations should be ‘dialling up the S’ in their sustainability initiatives.
  • [Webinar] Real-World Evidence: Empowering the Patient
    Healthcare Webinar

    [Replay] Real-World Evidence: Empowering the Patient

    Patient voices are now central to regulatory, HTA and commercial decisions. But how do we move beyond tick-box engagement to evidence that truly reflects lived experience? Join our expert panel for a 360° perspective on making patient-centricity work in practice.